The report "Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021", provides a detailed overview of drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the plasma therapy market, along with estimates and forecast of the revenue and market share analysis.
Browse 141 market data Tables and 98 Figures spread through 210 Pages and in-depth TOC on "Plasma Therapy Market”
The global plasma therapy market is segmented on the basis of type, source, application, end user, and region. Among all types, the pure PRP segment is estimated to account for the largest share of the global plasma therapy market in 2016. This segment is projected to grow at the highest CAGR from 2016 to 2021.
On the basis of source, the plasma therapy market is segmented into autologous and allogenic. The autologous segment is estimated to account for the largest share of the global plasma therapy market in 2016, owing to its safety and effective results. Prevalence of orthopedic disorders such as arthritis and tendinitis has propelled the demand for advanced treatment options. This has further contributed to the growth of the plasma therapy market.
On the basis of application, the plasma therapy market is segmented into dermatology, cardiac muscle injury, dental, nerve injury, and others. The orthopedic segment is further categorized into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is classified into androgenic alopecia and plastic surgery. Among all applications, the dermatology segment is expected to grow at a high CAGR from 2016 to 2021, owing to increase in the adoption of cosmetic procedures and prevalence of dermatological disorders such as androgenic alopecia.
With respect to end user, the plasma therapy market is segmented into hospitals & clinics and research institutes. The hospitals & clinics segment is estimated to account for the largest share of the global plasma therapy market in 2016. Rise in healthcare spending has resulted in the increasing use of platelet-rich plasma therapy (PRP) in hospitals & clinics.
Based on region, the global plasma therapy market is segmented into North America, Europe, Asia-Pacific, and rest of the world (RoW). North America is estimated to account for the largest share of the global plasma therapy market in 2016. This large share is mainly attributed to the increase in aging population and initiatives undertaken by the government to support developments in the field of plasma therapy.
Get The PDF Brochure for This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=186196333
Geographically, the market is led by North America, followed by Europe, Asia-Pacific, and rest of the world (RoW). Growth in the global market is primarily driven by the increase in aging population and rise in the number of orthopedic disorders.
• Company Information: Detailed company profiles of five or more market players
• Opportunities Assessment: A detailed report underlining various growth opportunities presented in the market
Value Addition for the Buyer:
This report aims to provide insights into the global plasma therapy market. It provides valuable information on plasma types, sources, applications, and end users in the market. Furthermore, it also provides a regional analysis of the market. Leading players are profiled in the report to study their product offerings and understand the strategies undertaken by them to sustain their competitive position in this market.
Request a sample of the report:
Major players in the plasma therapy market include BioLife Plasma Services (U.S.), Cambryn Biologics LLC (U.S.), Biotest (Germany), CSL Ltd. (Australia), Grifols International S.A. (Spain), Kedrion S.p.A. (Italy), LFB (France), Bio Products Laboratory Ltd. (U.K.), China Biologic Products, Inc. (China), and Octapharma (Switzerland).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
E-mail: [email protected]